What the changes say
- The proposed Merck KGaA acquisition adds deal-completion, regulatory, shareholder-vote and $73-per-share transaction risks.
What changed since the prior 10-K
New
- NewStrategic and Operational Risks
The proposed acquisition of the Company by Merck KGaA, Darmstadt, Germany may disrupt or adversely affect our business, prospects, financial condition and results of operations
The proposed Merck KGaA acquisition could disrupt Bio-Techne or harm its results if required approvals or shareholder approval are not obtained.
- NewStrategic and Operational Risks
We have incurred and expect to continue to incur substantial transaction-related fees and costs in connection with the Merger
Legal, financial, accounting and other merger costs could materially hurt Bio-Techne, including costs incurred without benefit if the deal fails.
- NewStrategic and Operational Risks
The Merger may not be completed within the expected timeframe, or at all, and a significant delay in or the failure to complete the Merger could adversely affect our business and the market price of our common stock
The merger could be delayed or fail because of shareholder, antitrust, investment-screening or other closing conditions, affecting the business and stock price.
- NewStrategic and Operational Risks
The Merger Agreement contains provisions that could discourage a potential competing acquirer of the Company or could result in a competing proposal being made at a lower price than it otherwise might have been
Limits on soliciting competing bids and an approximately $230.5 million termination fee could deter a higher competing acquisition offer.
- NewLegal, Regulatory, Compliance and Reputational Risks
government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment
Noncompliance with FDA, DEA, DHHS, USDA, APHIS and other regulations could suspend government contracts or cause criminal, civil, administrative penalties or debarment.
Reworded
- 84% rewrittenLegal, Regulatory, Compliance and Reputational Risks
Our business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results
No substantive wording change is shown; the risk still covers broad medical-device, healthcare, trade, anticorruption and privacy regulation.
- 77% rewrittenFinancial and Tax Risks
Dividends on our common stock could be reduced or eliminated in the future
The existing dividend-reduction risk now adds merger restrictions limiting dividends to regular quarterly cash payments consistent with past policy.
- 35% rewritten
The healthcare and life sciences industries that we serve face constant pressures and changes in an effort to reduce healthcare costs or increase their predictability, all of which may adversely affect our business and financial results
No substantive wording change is shown; the risk still covers customer research funding, healthcare reimbursement and government spending pressures.
All 29 risk factors
Headings as the filing states them, in filing order.
Other
- 01Economic and Industry Risks
- 02Conditions in the global economy, the particular markets we serve and the financial markets, whether brought about by material global crises or other factors, may adversely affect our business and financial results
- 03International political, compliance and business factors, including the military conflicts and trade tensions, can negatively impact our operations and financial results
- 04The healthcare and life sciences industries that we serve face constant pressures and changes in an effort to reduce healthcare costs or increase their predictability, all of which may adversely affect our business and financial results35% rewritten
- 05Our inability to complete acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price
- 06Our acquisition of businesses, investments, joint ventures and other strategic relationships, if not properly implemented or integrated, could negatively impact our business and financial results
- 07We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets or other investments become impaired, which could negatively impact our financial results or stock price
Strategic and Operational Risks
- 08Our success will be dependent on recruiting and retaining highly qualified and diverse personnel and creating and maintaining a culture that successfully integrates the employees joining through acquisitions
- 09Our growth depends in part on the timely development and commercialization of new and enhanced products and services that meet our customers ’ needs. Our growth can also be negatively impacted if our customers do not grow as anticipated
- 10We face intense competition, and if we are unable to compete effectively, we may experience decreased demand and decreased market share or need to reduce prices to remain competitive
- 11A significant disruption in, or breach of security of, our information technology systems or data, or violation of data privacy laws, could result in damage to our reputation, data integrity and/or subject us to costs, fines, or lawsuits under data privacy or other laws or contractual requirements
- 12If we suffer loss to our supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed
- 13The manufacture of many of our products is a complex process, and in many cases subject to complex regulations, and if we directly or indirectly encounter problems manufacturing products, our business and financial results could suffer
- 14The Company relies heavily on internal manufacturing and related operations to produce, package and distribute its products which, if disrupted, could materially impair our business operations. Our business could be adversely affected by disruptions at our sites
- 15Climate change and/or related environmental risks, or legal or regulatory measures to address climate change and/or related environmental risks, may negatively affect us
- 16Defects, unanticipated use of, or inadequate disclosure with respect to our products, or allegations thereof, can adversely affect our business and financial results
- 17Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability
- 18The proposed acquisition of the Company by Merck KGaA, Darmstadt, Germany may disrupt or adversely affect our business, prospects, financial condition and results of operationsNew
- 19We have incurred and expect to continue to incur substantial transaction-related fees and costs in connection with the MergerNew
- 20The Merger may not be completed within the expected timeframe, or at all, and a significant delay in or the failure to complete the Merger could adversely affect our business and the market price of our common stockNew
- 21The Merger Agreement contains provisions that could discourage a potential competing acquirer of the Company or could result in a competing proposal being made at a lower price than it otherwise might have beenNew
- 22We are dependent on maintaining our intellectual property rights. If we are unable to adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights
- 23We may be involved in disputes to determine the scope, coverage and validity of others’ proprietary rights, or to defend against third-party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business
Financial and Tax Risks
- 24We have entered into and drawn on a revolving credit facility, and we may incur additional debt in the future. The burden of this additional debt could adversely affect us, make us more vulnerable to adverse economic or industry conditions, and prevent us from funding our expansion strategy
- 25Our business and financial results can be adversely affected by foreign currency exchange rates, changes in our tax rates and tax liabilities and assessments (including as a result of changes in tax laws)
- 26Dividends on our common stock could be reduced or eliminated in the future77% rewritten
Legal, Regulatory, Compliance and Reputational Risks
- 27Our business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results84% rewritten
- 28government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarmentNew
- 29Our business and financial results can be impaired by improper conduct by any of our employees, agents or business partners
Other Bio-Techne 10-Ks
- FY2025 10-K risk factors24 risks
International sales drive 44% of revenue, exposing Bio-Techne to global trade and geopolitical tensions. Acquisition strategy and integration risks are critical for growth in Protein Sciences. Heavy reliance on internal manufacturing and third-party cold-chain delivery creates operational vulnerabilities.
Filed Aug 22, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.